Hot Biotech Stocks To Watch Right Now: Array BioPharma Inc. (ARRY), OvaScience, Inc. (OVAS)
Array BioPharma Inc. (ARRY) ended last trading session with a change of 4.09 percent. It trades at an average volume of 4.04M shares versus 3.15M shares recorded at the end of last trading session. The share price of $11.44 is at a distance of 357.6 percent from its 52-week low and down -14.63 percent versus its peak. The company has a market cap of $2.01B and currently has 175.62M shares outstanding. The share price is currently 0.32 percent versus its SMA20, 6.31 percent versus its SMA50, and 74.13 percent versus its SMA200. The stock has a weekly performance of -2.05 percent and is 30.15 percent year-to-date as of the recent close.
On Feb. 9, 2017 Array BioPharma Inc. (ARRY) reported results for its second quarter of fiscal 2017 and provided an update on the progress of its key clinical development programs.
“We were pleased to report that COLUMBUS met its primary endpoint and demonstrated a robust PFS benefit associated with the combination of binimetinib plus encorafenib versus vemurafenib in patients with BRAF-mutant melanoma,” said Ron Squarer, Chief Executive Officer of Array BioPharma. “Following a pre-NDA meeting with the FDA, we expect to file an NDA for COLUMBUS in June or July.”
OvaScience, Inc. (OVAS) recently recorded 8.11 percent change and currently at $1.6 is 23.08 percent away from its 52-week low and down -86.28 percent versus its peak. It has a past 5-day performance of 12.68 percent and trades at an average volume of 1.27M shares. The stock has a 1-month performance of 5.96 percent and is 4.58 percent year-to-date as of the recent close. There were about 34.66M shares outstanding which made its market cap $55.46M. The share price is currently 7.78 percent versus its SMA20, 3.23 percent versus its SMA50, and -64.38 percent versus its SMA200.
On March 3, 2017 OvaScience, Inc. (OVAS) reported financial results and provided a business update for the on fourth quarter and year ended December 31, 2016.
“We are entering 2017 with continued confidence in our portfolio of potentially transformative fertility treatments and a strong belief in the potential of our EggPC platform to help women and couples build the families they deserve,” said Michelle Dipp, M.D., Ph.D., Executive Chair and Co-Founder of OvaScience.
“In 2016, we achieved criteria indicative of developmental competence in EggPC cell-derived bovine and human eggs, an important step in the preclinical development of OvaTure, and we are on track to successfully fertilize a bovine EggPC cell-derived egg by year-end,” added Christophe Couturier, Chief Financial Officer. “We are also pleased to have enrolled the first 50 patients in our company-sponsored trial of OvaPrime, and to have started performing the first biopsies and reintroductions. With these milestones in hand, we remain on track to report initial data on our first 20 patients from this study by year-end. We are sufficiently funded to support the preclinical development of OvaTure and clinical development of OvaPrime into the first quarter of 2019.”